Navigation Links
CSM Appoints Michael Morse as Vice President of Finance
Date:7/7/2015

CSM, a leading clinical trial supply company, today announced that Michael Morse has joined the executive team as Vice President of Finance. Morse has an extensive background in financial management and accounting, bringing over 20 years of experience in the biotechnology and pharmaceutical industries to the CSM team. In his new role, Morse will oversee all financial areas of the company to both strengthen CSM’s financial strategy and meet overall company goals and objectives.

“We welcome Michael to CSM,” said Gerald Finken, CSM’s President and CEO. “I know he will be a tremendous addition to our executive team and continue to raise the bar in our commitment to excellence. Michael’s breadth of financial experience in the healthcare industry will not only support our current strategic plan, but will also help CSM move forward in the next stage of our global development,” said Finken.

With CSM’s growth and continued expansion both in the US and internationally, this role will be crucial in supporting the company’s strategic planning for long-term financial success. As Vice President of Finance, Morse will be responsible for budgeting, forecasting, cash flow management, taxation, and financial planning and reporting.

Prior to joining CSM, Morse was the Director of Finance for Genzyme Corporation, a publicly traded, billion-dollar biopharmaceutical company. During his 10+ years at Genzyme, Morse directed the financial operations of three Research and Development (R&D) units and managed the financial impact of a large-scale clinical trial.

“I am very excited to take on this new role and work closely with CSM’s executive team and key stakeholders,” said Morse. “I look forward to being an integral part of such a fast-growing company and am eager to start contributing.”

Morse is a Certified Public Accountant in Massachusetts and Chartered Global Management Accountant. He holds a BS from Bentley University, an MBA from Boston University, and a Master of Taxation from Bentley University.

About CSM
CSM provides clinical trial supply services with quality-driven processes to enhance biotechnology and pharmaceutical clinical trials worldwide. The company has continued to evolve with its blend of unique and traditional clinical trial services that improve efficiency and accuracy.

CSM is the innovator of On-Demand Packaging and Labeling services, an industry breakthrough in which clinical supplies are made specifically for, and immediately prior to, each shipment. Some of CSM’s other core services include: traditional packaging and labeling, cold chain logistics, controlled drug services, returns and reconciliation, clinical label printing and global distribution. For more information, visit http://www.csmondemand.com

Read the full story at http://www.prweb.com/releases/2015/06/prweb12794944.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. ProNAi Appoints Dr. Barbara Klencke as Chief Development Officer
2. ProNAi Appoints Dr. Nicole Onetto and Mr. Robert Pelzer to its Board of Directors
3. Bioniz Appoints Pharmaceutical Industry Legend David Pyott to its Board of Directors
4. PTC Therapeutics Appoints Glenn D. Steele Jr., M.D., Ph.D. to Board of Directors
5. China Cord Blood Corporations Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal
6. Creabilis Appoints Catherine Moukheibir as Chairman of its Board of Directors
7. Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology
8. AlphaImpactRx Appoints Darrell Philpot Senior Vice President, Analytics And Chief Methodologist
9. Kiadis Pharma Appoints Dr. Vincent Brichard to its Supervisory Board
10. Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board
11. Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... July 17, 2020 , ... ... firm for the life sciences and food industries, is pleased to announce that ... Clinical Research – Business Development. , Charles is an accomplished and results-driven sales ...
(Date:7/10/2020)... Mass. (PRWEB) , ... July 09, 2020 , ... ... approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., ... team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. ...
(Date:7/1/2020)... ... June 29, 2020 , ... The ... purchasing contracts to its membership, recently named BioFit Engineered Products an ... opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts at discounted ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... therapy for treating cancer, today announced the company has entered a license agreement ... The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding ...
Breaking Biology Technology:
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
Breaking Biology News(10 mins):